Peripheral administration of proteins including TGF-beta superfamily members for systemic treatment of disorders and disease

Peripheral administration of proteins including TGF-beta superfamily members for systemic treatment of disorders and disease

Abstract The present invention is directed to methods and compositions for accomplishing systemic delivery of minimally-soluble bioactive agents such as, but not limited to, proteins of the TGF-p superfamily via a peripheral mode of administration. 5 According to the invention, an exemplary bioactiv...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: HASKELL, MELISSA M, SCHRIER, DENIS, GOAD, MARY ELIZABETH PECQUET, WOOD, SUSAN A
Format: Patent
Sprache:eng
Schlagworte:
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator HASKELL, MELISSA M
SCHRIER, DENIS
GOAD, MARY ELIZABETH PECQUET
WOOD, SUSAN A
description Abstract The present invention is directed to methods and compositions for accomplishing systemic delivery of minimally-soluble bioactive agents such as, but not limited to, proteins of the TGF-p superfamily via a peripheral mode of administration. 5 According to the invention, an exemplary bioactive agent is BMP-7. The invention further provides for minimally-invasive systemic treatment of skeletal disorders such as osteoporosis as well as minimally-invasive systemic treatment of injured or diseased non-mineralized tissues and organs such kidneys. Practice of the invention eliminates adverse side effects at the peripheral site of intravenous administration of the bioactive 10 agent. 4422738_i (GHMatters) P87733.AU 1
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_AU2013206499A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>AU2013206499A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_AU2013206499A13</originalsourceid><addsrcrecordid>eNqNjDkKAlEQBScxEPUODcaCG8KEIi6hgcbSzn-jDfMXuttA8PAy4AGMioKihtXnDJXyhHJHHKIkMVd2yYlyS0WzQ5KRpKZ7BUkPuhwPszucyV4F2nKU7k0R8Q41arOSvc0RpSFXsEck709BLGvoG06hN7BhXA1a7gyTH0fV9LC_7E4zlHyDFW6Q4LftdTlfrJbzzbqut4vVf9UXp15Jeg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Peripheral administration of proteins including TGF-beta superfamily members for systemic treatment of disorders and disease</title><source>esp@cenet</source><creator>HASKELL, MELISSA M ; SCHRIER, DENIS ; GOAD, MARY ELIZABETH PECQUET ; WOOD, SUSAN A</creator><creatorcontrib>HASKELL, MELISSA M ; SCHRIER, DENIS ; GOAD, MARY ELIZABETH PECQUET ; WOOD, SUSAN A</creatorcontrib><description>Abstract The present invention is directed to methods and compositions for accomplishing systemic delivery of minimally-soluble bioactive agents such as, but not limited to, proteins of the TGF-p superfamily via a peripheral mode of administration. 5 According to the invention, an exemplary bioactive agent is BMP-7. The invention further provides for minimally-invasive systemic treatment of skeletal disorders such as osteoporosis as well as minimally-invasive systemic treatment of injured or diseased non-mineralized tissues and organs such kidneys. Practice of the invention eliminates adverse side effects at the peripheral site of intravenous administration of the bioactive 10 agent. 4422738_i (GHMatters) P87733.AU 1</description><language>eng</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><creationdate>2013</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20130711&amp;DB=EPODOC&amp;CC=AU&amp;NR=2013206499A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20130711&amp;DB=EPODOC&amp;CC=AU&amp;NR=2013206499A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>HASKELL, MELISSA M</creatorcontrib><creatorcontrib>SCHRIER, DENIS</creatorcontrib><creatorcontrib>GOAD, MARY ELIZABETH PECQUET</creatorcontrib><creatorcontrib>WOOD, SUSAN A</creatorcontrib><title>Peripheral administration of proteins including TGF-beta superfamily members for systemic treatment of disorders and disease</title><description>Abstract The present invention is directed to methods and compositions for accomplishing systemic delivery of minimally-soluble bioactive agents such as, but not limited to, proteins of the TGF-p superfamily via a peripheral mode of administration. 5 According to the invention, an exemplary bioactive agent is BMP-7. The invention further provides for minimally-invasive systemic treatment of skeletal disorders such as osteoporosis as well as minimally-invasive systemic treatment of injured or diseased non-mineralized tissues and organs such kidneys. Practice of the invention eliminates adverse side effects at the peripheral site of intravenous administration of the bioactive 10 agent. 4422738_i (GHMatters) P87733.AU 1</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2013</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNjDkKAlEQBScxEPUODcaCG8KEIi6hgcbSzn-jDfMXuttA8PAy4AGMioKihtXnDJXyhHJHHKIkMVd2yYlyS0WzQ5KRpKZ7BUkPuhwPszucyV4F2nKU7k0R8Q41arOSvc0RpSFXsEck709BLGvoG06hN7BhXA1a7gyTH0fV9LC_7E4zlHyDFW6Q4LftdTlfrJbzzbqut4vVf9UXp15Jeg</recordid><startdate>20130711</startdate><enddate>20130711</enddate><creator>HASKELL, MELISSA M</creator><creator>SCHRIER, DENIS</creator><creator>GOAD, MARY ELIZABETH PECQUET</creator><creator>WOOD, SUSAN A</creator><scope>EVB</scope></search><sort><creationdate>20130711</creationdate><title>Peripheral administration of proteins including TGF-beta superfamily members for systemic treatment of disorders and disease</title><author>HASKELL, MELISSA M ; SCHRIER, DENIS ; GOAD, MARY ELIZABETH PECQUET ; WOOD, SUSAN A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_AU2013206499A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2013</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><toplevel>online_resources</toplevel><creatorcontrib>HASKELL, MELISSA M</creatorcontrib><creatorcontrib>SCHRIER, DENIS</creatorcontrib><creatorcontrib>GOAD, MARY ELIZABETH PECQUET</creatorcontrib><creatorcontrib>WOOD, SUSAN A</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>HASKELL, MELISSA M</au><au>SCHRIER, DENIS</au><au>GOAD, MARY ELIZABETH PECQUET</au><au>WOOD, SUSAN A</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Peripheral administration of proteins including TGF-beta superfamily members for systemic treatment of disorders and disease</title><date>2013-07-11</date><risdate>2013</risdate><abstract>Abstract The present invention is directed to methods and compositions for accomplishing systemic delivery of minimally-soluble bioactive agents such as, but not limited to, proteins of the TGF-p superfamily via a peripheral mode of administration. 5 According to the invention, an exemplary bioactive agent is BMP-7. The invention further provides for minimally-invasive systemic treatment of skeletal disorders such as osteoporosis as well as minimally-invasive systemic treatment of injured or diseased non-mineralized tissues and organs such kidneys. Practice of the invention eliminates adverse side effects at the peripheral site of intravenous administration of the bioactive 10 agent. 4422738_i (GHMatters) P87733.AU 1</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language eng
recordid cdi_epo_espacenet_AU2013206499A1
source esp@cenet
subjects HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
title Peripheral administration of proteins including TGF-beta superfamily members for systemic treatment of disorders and disease
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T23%3A21%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=HASKELL,%20MELISSA%20M&rft.date=2013-07-11&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EAU2013206499A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true